Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry.
Atherosclerosis
Cholesterol, LDL
Coronary Artery Disease
/ diagnostic imaging
Diabetes Mellitus, Type 2
/ complications
Disease Progression
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Lipoprotein(a)
Percutaneous Coronary Intervention
Plaque, Atherosclerotic
Registries
Risk Factors
LDL-C
Lipid-rich plaque
Lipoprotein (a)
Near-infrared spectroscopy
Type 2 diabetes mellitus
Journal
Atherosclerosis
ISSN: 1879-1484
Titre abrégé: Atherosclerosis
Pays: Ireland
ID NLM: 0242543
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
06
11
2021
revised:
24
03
2022
accepted:
30
03
2022
pubmed:
23
4
2022
medline:
26
5
2022
entrez:
22
4
2022
Statut:
ppublish
Résumé
The residual risk of atherosclerotic cardiovascular disease (ASCVD) in patients with diabetes on statin therapy warrants identification of other pro-atherogenic drivers. Lipoprotein(a) [Lp(a)] promotes the formation of necrotic cores within vessel walls. Given that patients with diabetes have an Lp(a)-associated ASCVD risk, Lp(a) might lead to plaque vulnerability in patients with diabetes on statin therapy. We analyzed target lesions that underwent PCI in 312 patients with coronary artery disease (CAD) on statin treatment from the REASSURE-NIRS registry (NCT04864171). Maximum 4-mm lipid-core-burden index (maxLCBI High-intensity statin use (p = 0.49) and on-treatment low-density lipoprotein cholesterol (LDL-C) (p = 0.32) and Lp(a) levels (p = 0.09) were comparable between patients with and without diabetes. Lp(a) levels were significantly associated with maxLCBI A significant relationship between Lp(a) and maxLCBI
Sections du résumé
BACKGROUND AND AIMS
The residual risk of atherosclerotic cardiovascular disease (ASCVD) in patients with diabetes on statin therapy warrants identification of other pro-atherogenic drivers. Lipoprotein(a) [Lp(a)] promotes the formation of necrotic cores within vessel walls. Given that patients with diabetes have an Lp(a)-associated ASCVD risk, Lp(a) might lead to plaque vulnerability in patients with diabetes on statin therapy.
METHODS
We analyzed target lesions that underwent PCI in 312 patients with coronary artery disease (CAD) on statin treatment from the REASSURE-NIRS registry (NCT04864171). Maximum 4-mm lipid-core-burden index (maxLCBI
RESULTS
High-intensity statin use (p = 0.49) and on-treatment low-density lipoprotein cholesterol (LDL-C) (p = 0.32) and Lp(a) levels (p = 0.09) were comparable between patients with and without diabetes. Lp(a) levels were significantly associated with maxLCBI
CONCLUSIONS
A significant relationship between Lp(a) and maxLCBI
Identifiants
pubmed: 35450750
pii: S0021-9150(22)00166-6
doi: 10.1016/j.atherosclerosis.2022.03.033
pii:
doi:
Substances chimiques
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Lipoprotein(a)
0
Banques de données
ClinicalTrials.gov
['NCT04864171']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
183-189Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.